J&J tops out Barron's list of Best Companies, for 2nd year in a row. Generic competitors awake to Sepracor's Lunesta - Drug maker Sepracor Inc. said two competitors have filed applications to …
Pharma News 3_29
Breaking news from the ACC: Vytorin/Zetia gets panned - shows no benefit on the primary endpoint, though effective in reducing some markers. Doctors now wary and skeptical. Merck and Schering-Plough …